Dr Nelli Bejanyan, MD

Dr. Bejanyan is a Senior Member and Program Leader of the Blood and Marrow Transplant and Cellular Immunotherapy (BMT CI) program, as well as the Head of the Leukemia/Myeloid Section within the BMT and Cellular Immunotherapy Department at Moffitt Cancer Center. She is also a Professor in Oncologic Sciences at the University of South Florida.With extensive clinical and research expertise in BMT and cellular immunotherapies for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), Dr. Bejanyan is dedicated to advancing both clinical and translational research. She focuses on pioneering immune cell therapy strategies to treat leukemia. Dr. Bejanyan is the Principal Investigator (PI) and Co-PI of several cellular immunotherapy clinical trials for AML, including an innovative first-in-human clinical trial using donor-derived, expanded anticancer gamma delta T cells to treat high-risk AML following BMT. In addition to her research contributions, Dr. Bejanyan plays a pivotal role …in the broader scientific community. She serves as Co-chair of the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) and is a member of several esteemed committees, including the International Expert Panel for the AML Relapse Committee, the ASTCT MDS Expert Panel Committee, the BMT CTN Steering Committee, the BMT CTN State of the Science Symposium Myeloid Malignancy Committee, and the CIBMTR Proposal Task Force.